Chronic myelogenous leukemia (CML) and Ph-positive acute lymphoblastic leukemia (ALL) are caused by the fusion of the BCR gene to the ABL gene, which encodes a tyrosine kinase. The P190 and P210 are two main chimeric forms of the Bcr/Abl protein, with the P190 frequently associated with cases of ALL and P210 predominantly occurring in CML. 1 Development of inhibitors such as Imatinib, which specifically target the deregulated Bcr/Abl tyrosine kinase, has revolutionized the treatment of CML. 2 However, Philadelphia-positive ALL has a much less durable response to Imatinib and treatment options remain limited. 3 Therefore, the identification of signal transduction pathways that are perturbed by Bcr/Abl has become an important area of investigation, aiming to find additional molecular targets for treating this type of cancer. 4 We have previously identified the catalytic subunit of the serine/threonine kinase CK2 as an interacting partner for the Bcr/ Abl oncoprotein. 5 CK2 activity is elevated in many kinds of tumors. 6, 7 Very specific inhibitors of CK2 have been developed. In previous experiments, we showed that one of these inhibitors, 4,5,6,7-tetrabromobenzimidazole (TBB), inhibited the growth of malignant pre-B lymphoblastic leukemia cells that express Bcr/ Abl P190. 5 However, this required relatively high concentrations of 60 mM TBB, to achieve this effect. We therefore compared TBB to a newly developed CK2 inhibitor, 2-dimethylamino-4,5,6,7-tetrabromo-1H-benzimidazole (DMAT). DMAT has the lowest K(i) value of all known CK2 inhibitors, and is cell permeable. 8 Based on reported ranges of efficacy, 7, 8 DMAT was tested at 5, 10 and 20 mM. We used the previously described PLC1 cell line, which was established from a P190 Bcr/Abl transgenic mouse that developed pro/pre-B lymphoblastic leukemia/lymphoma. 5 PLC1 cells were standardly maintained on irradiated primary mouse embryonic fibroblast feeder layers (MEFs). Cell viability was assessed on aliquots from individual wells using the trypan blue dye exclusion method. As shown in Figure 1a , 10 mM DMAT was very effective in inhibiting the proliferation of the lymphoblastic leukemia cells over a period of 2 days, and was superior to treatment with 60 mM TBB. At 22 h, there were no viable cells remaining in the wells treated with 20 mM DMAT (not shown). Treatment of two other leukemia lines derived from different individual BCR/ABL transgenic mice confirmed the effect of this drug on the leukemia cells ( Figure 1b ). We also treated normal primary mouse fibroblasts with 10 mM DMAT to assess possible toxicity of this drug. As shown in Figure 1c , the drug inhibited proliferation of these cells, but did not cause significant cell death. Also, kidney, bone marrow and liver of mice treated for 25 days with twice daily intraperitoneal injections of 25 mg/kg DMAT were histologically normal (results not shown).
We routinely grow lymphoblastic leukemia cells in the presence of stroma to model drug treatment in the context of a defined microenvironment. However, as stroma is known to provide protection to lymphoblastic leukemia cells, we also evaluated the efficacy of DMAT in inhibiting proliferation of the leukemic cells under less protective conditions, in the absence of stroma. Moreover, drug studies performed by others usually do not include stromal support. As shown in Figure 2a , a large drop in viability was observed during the initial 2 days of treatment with 10 mM DMAT when the cells were co-cultured with stroma, but viable cells remained at 30 h. In contrast, when the cells were treated with DMAT in the absence of stromal support, almost no viable cells remained after 30 h of drug treatment (Figure 2b ). This shows that as a monotreatment, DMAT is able to effectively eradicate these malignant lymphoblasts.
Because of the potential problems of emerging drug resistance, therapy for human cancer is moving away from drug monotherapy, and towards treatment with more than one drug. Imatinib is the treatment of choice for CML, and therefore we evaluated the combined use of DMAT with Imatinib. As shown in Figure 3a , treatment with 10 mM Imatinib or 10 mM DMAT alone caused a substantial drop in cell viability over a period of Letters to the Editor 2 days. A combined treatment with both 10 mM Imatinib and 10 mM DMAT basically eradicated the entire culture at 22 h of treatment. Fluorescence-activated cell sorter (FACS) analysis was performed on PLC1 cells grown for 6 h in the presence of solvent (water and dimethyl sulfoxide (DMSO)), Imatinib, DMAT or Imatinib þ DMAT. A significant increase in the numbers of cells with a DNA content of less than N was seen, down from 21% in cells treated with water and DMSO to 32% with Imatinib, 43% with 10 mM DMAT and 68% with 10 mM DMAT þ Imatinib (Figure 3b ). Very few cells in the population treated with both drugs were present in the G 2 /M phase of the cell cycle (Figure 3b, right panel) . Together, these results show that an increased percentage of cells were apoptotic when treated with both drugs.
We further examined the combined treatment with DMAT and Imatinib. We first treated the cells with 10 mM DMAT and varied the treatment with Imatinib from 0 to 2.5 mM. The viability of the cells dropped to 30% after 24 h of treatment with DMAT alone, and was further reduced after 2 days of treatment. Consistent with the results in Figures 2a and 3a however, some viable cells persisted in the culture. The addition of Imatinib clearly resulted in a further decrease in viable cell numbers, and with the addition of 1.25 mM drug, all cells were killed within 34 h (Figure 3c ). As the combination of 10 mM Imatinib with 10 mM DMAT rapidly killed the cells (Figure 3a) , we also treated the cells with a lower fixed concentration of 5 mM Imatinib and added 0-5 mM DMAT to the cultures. Treatment with 5 mM Imatinib alone for 24 h caused a decrease to 55% in cell viability and the addition of DMAT further enhanced this effect (Figure 3d ).
Taken together, these results show that inhibitors of the serine/ threonine kinase CK2 may be useful either as monotherapy or even more potent in combination therapy with the tyrosine kinase inhibitor, Imatinib, for the treatment of leukemias caused by the Bcr/Abl oncogene. In the preclinical model used here, we have shown that especially the combination of the two drugs may be useful in eradicating cells that appear to linger after the initial treatment with a single drug, an effect that is prominent in the presence of stroma (Figure 2) . However, the pharmacokinetics of this novel CK2 inhibitor, such as drug stability and activity, are not known and therefore, further preclinical studies will be needed to evaluate its biological activity in animals before it can be tested for the treatment of cancer. 
Letters to the Editor
About 50% of tumor metastasis is via the lymphatic system, but the underlying mechanisms have not been characterized. L-selectin (CD62L) is a lymphocyte homing receptor that is important for the migration of lymphocytes into peripheral lymph nodes. 1 It is an intriguing question whether lymphoma cells use the same pathways of dissemination into peripheral lymph nodes. [2] [3] In this work, we sought to ascertain whether the expression of L-selectin on macrophage-like lymphoid neoplasm P388D1 cells would facilitate their localization to peripheral lymph nodes. 

